Document Detail

The IGF system after insertion of a transjugular intrahepatic porto-systemic shunt in patients with liver cirrhosis.
MedLine Citation:
PMID:  19336524     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: Insertion of a transjugular intrahepatic porto-systemic shunt (TIPS) into patients with liver cirrhosis usually induces a gain in body cell mass. Changes in the IGF system in favor of anabolism may be involved. We, therefore measured blood concentrations of the components of the IGF system in cirrhosis patients before and after elective TIPS. DESIGN AND METHODS: The study comprised 17 patients and 11 healthy controls. Patients were examined before and 1, 4, 12, and 52 weeks after TIPS. Biochemical analyses of the IGF system were compared with changes in body composition (bioimpedance analysis), glucose and insulin, and metabolic liver function (galactose elimination capacity). RESULTS: After TIPS, body cell mass rose by 3.2 kg (95% confidence interval (CI): 1.0-5.5) at 52 weeks, in correlation with baseline liver function (r(2)=0.22; P=0.03). Peripheral blood concentrations of total IGF1 and 2, bioactive IGF1, and the IGF-binding proteins (IGFBP-1, -2, and -3) remained unchanged throughout the study period. There was no change in fasting glucose, whereas fasting insulin rose by 40% (CI: 11-77%) and glucagon by 58% (CI: 11-132%) from baseline to 52 weeks after TIPS. CONCLUSION: Our data confirm that TIPS was associated with an increase in body cell mass in patients with liver cirrhosis, but without any change in the circulating IGF system. Thus, the results do not support the notion that effects on the circulating IGF system are involved in the anabolic effects of TIPS insertion.
Peter Holland-Fischer; Hendrik Vilstrup; Jan Frystyk; Dennis Tønner Nielsen; Allan Flyvbjerg; Henning Grønbaek
Related Documents :
2129814 - Immunological profile of patients with non-cirrhotic portal fibrosis.
15123374 - Oral glutamine challenge and magnetic resonance spectroscopy in three patients with con...
7461504 - Antithrombin iii versus prothrombin in liver cirrhosis.
14696404 - Usefulness of per-rectal portal scintigraphy with technetium-99m pertechnetate for prog...
17709664 - Chronic urticaria and monoclonal igm gammopathy (schnitzler syndrome): report of 11 cas...
7712994 - The role of endoscopic ultrasonography in biliary tract disease: obstructive jaundice.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-03-31
Journal Detail:
Title:  European journal of endocrinology / European Federation of Endocrine Societies     Volume:  160     ISSN:  1479-683X     ISO Abbreviation:  Eur. J. Endocrinol.     Publication Date:  2009 Jun 
Date Detail:
Created Date:  2009-05-12     Completed Date:  2009-06-02     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9423848     Medline TA:  Eur J Endocrinol     Country:  England    
Other Details:
Languages:  eng     Pagination:  957-63     Citation Subset:  IM    
Department of Medicine V (Hepatology and Gastroenterology), Aarhus University Hospital, Noerrebrogade 44, 8000 Aarhus C, Denmark.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Glucose / analysis
Body Composition
Dietary Proteins / metabolism
Energy Intake
Insulin-Like Growth Factor Binding Proteins / blood*
Liver / metabolism
Liver Cirrhosis / blood,  metabolism*,  surgery*
Middle Aged
Portasystemic Shunt, Transjugular Intrahepatic / adverse effects*
Somatomedins / metabolism*
Reg. No./Substance:
0/Blood Glucose; 0/Dietary Proteins; 0/Insulin-Like Growth Factor Binding Proteins; 0/Somatomedins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A novel a33 promoter-based conditionally replicative adenovirus suppresses tumor growth and eradicat...
Next Document:  The spermostatic and microbicidal actions of quinones and maleimides: toward a dual-purpose contrace...